Skip to main content
. 2022 Nov 8;13:874028. doi: 10.3389/fphar.2022.874028

TABLE 3.

PFS at the PMA-ZEO 7-month time point for cancer progression events in first-line treatment patients.

Progression-free survival N°events/total Median time (95% CI) p-value
Groups 0.05
Placebo group 22/27 7.23 (5.48–7.48)
PMA-ZEO 25/27 7.73 (6.83–9.13)